Loading news...
/PRNewswire/ -- USA News Group News Commentary - Global capital is officially rotating into "Longevity Infrastructure" which is now valued at a massive $27
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 first quarter ended December 31, 2026. Webcast and Conference Call Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately.
Bayforest Capital Ltd reduced its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) by 90.5% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,644 shares of the biotechnology company's stock after selling 53,759 shares during the period. Bayforest Capital Ltd's holdings
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, for a transaction value of ~$5,443,462. This sale represented 2.17% of Mr.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potent.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) shared initial interim clinical results from two RNA interference (RNAi) obesity candidates, ARO-INHBE and ARO-ALK7, during a virtual key opinion leader (KOL) event featuring metabolic medicine expert Dr. Carel le Roux and company leadership. Executives emphasized that the data are early, but described the readouts as supportive of the therapeutic hypothesis that
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 milli.
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript
Arrowhead Pharmaceuticals, Inc. shares rose on early data from obesity candidates ARO-INHBE and ARO-ALK7, but I have more questions than answers. INHBE-targeted monotherapy is unlikely to drive meaningful weight loss. Combination data with tirzepatide showed promising weight loss, but tiny sample sizes and missing datasets raise concerns about the true efficacy.
Arrowhead's experimental therapy helped patients on Lilly's Zepbound lose more weight and visceral fat—but cost and convenience could limit demand.
Arrowhead, Inc. (NASDAQ: ARWR) on Tuesday shared interim results from two Phase 1/2a trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics for obesity.
Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being developed as potential treatments for obesity. Preliminary results with Arrowhead's promising new approach to treating obesity and metabolic diseases showed meaningful reductions in multiple key measures, including visceral fat, total fat, and liver.
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that Health Canada has issued a Notice of Compliance (NOC) authorizing REDEMPLO™ (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for whom standard triglyceride lowering therapies have been inadequate. FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 ti.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) Director Mauro Ferrari sold 7,530 shares of the stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $70.00, for a total value of $527,100.00. Following the transaction, the director directly owned 69,053 shares of the company's stock,
HBK Sorce Advisory LLC acquired a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 76,408 shares of the biotechnology company's stock, valued at approximately $2,823,000. HBK Sorce Advisory LLC owned 0.06% of Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 13,445 shares of the business's stock in a transaction on Friday, December 19th. The stock was sold at an average price of $67.66, for a total transaction of $909,688.70. Following the sale, the chief executive officer owned 3,818,512 shares in the company,